Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 13/20 | 0.53 |
| ▸ | MAP2K2 | P36507 | 9/20 | 0.53 |
| ▸ | DHODH | Q02127 | 6/20 | 0.42 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.40 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14748182 | 0.89 | MAP2K1 (0.65) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL391338 | 0.88 | MAP2K1 (0.51) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL29425363 | 0.86 | MAP2K1 (0.69) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL13070282 | 0.86 | MAP2K1 (0.50) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL387684 | 0.86 | MAP2K1 (0.58) | MAP2K1MAP2K2 | |
| SCHEMBL486563 | 0.86 | MAP2K1 (0.69) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL27769414 | 0.84 | MAP2K1 (0.55) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL28221221 | 0.82 | MAP2K1 (0.47) | MAP2K1MAP2K2DHODH | |
| SCHEMBL13560149 | 0.81 | MAP2K1 (0.51) | MAP2K1MAP2K2DHODHMAP2K5EIF2AK1 | |
| SCHEMBL392252 | 0.80 | MAP2K1 (0.63) | MAP2K1MAP2K2MAP2K5EIF2AK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2251327-B1 | HETEROCYCLIC INHIBITORS OF MEK | ARRAY BIOPHARMA INC (US) | 2014-02-12 | — | — | EP | claimed |
| EP-1682138-B3 | HETEROCYCLIC INHIBITORS OF MEK | ARRAY BIOPHARMA INC (US) | 2013-01-09 | — | — | EP | claimed |
| CN-102633716-A | Bicyclic inhibitors of mek and methods of use thereof | ARRAY BIOPHARMA INC | 2012-08-15 | — | — | CN | claimed |
| US-8211921-B2 | Heterocyclic inhibitors of MEK and methods of use | ARRAY BIOPHARMA INC. (US) | 2012-07-03 | — | — | US | claimed |
| EP-2251327-A2 | Heterocyclic inhibitors of MEK and methods of use thereof | Array Biopharma, Inc. (US) | 2010-11-17 | — | — | EP | claimed |
| US-20090131435-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2009-05-21 | — | — | US | claimed |
| JP-2007511614-A | — | — | 2007-05-10 | — | — | JP | claimed |
| CN-1905873-A | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2007-01-31 | — | — | CN | claimed |
| EP-1682138-A4 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-01-24 | — | — | EP | claimed |
| EP-1682138-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-07-26 | — | — | EP | claimed |
| US-20050250782-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-10 | — | — | US | claimed |
| WO-2005051301-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | claimed |
| EP-2251327-B1 | HETEROCYCLIC INHIBITORS OF MEK | ARRAY BIOPHARMA INC (US) | 2014-02-12 | — | — | EP | disclosed |
| US-8431574-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20130018075-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2013-01-17 | — | — | US | disclosed |
| EP-1682138-B3 | HETEROCYCLIC INHIBITORS OF MEK | ARRAY BIOPHARMA INC (US) | 2013-01-09 | — | — | EP | disclosed |
| WO-2006056427-A1 | NOVEL 4-ARYLAMINO PYRIDONE DERIVATIVES AS MEK INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | LABORATOIRES SERONO S.A. (CH) | 2006-06-01 | — | — | WO | disclosed |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050250782-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-10 | — | — | US | disclosed |
| WO-2005051301-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131435-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE | NRAS, BRAF, MAPK9 | MAP2K1 88/4885MAP2K2 71/4885DHODH 998/4885 |
| US-20050250782-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | MAP2K1 87/4885MAP2K2 73/4885DHODH 1188/4885 |
| US-20130018075-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, RAF1 | MAP2K1 45/4885MAP2K2 34/4885DHODH 662/4885 |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | MAP2K1 82/4885MAP2K2 69/4885DHODH 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.